Effect of Magnesium on Neuromonitoring
Pharmacokinetics and Impact of Magnesium Sulfate on Neuromonitoring in Spinal Surgery
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Adult patients (\>18 years of age) undergoing open thoracolumbar fusion with planned neuromonitoring Exclusion Criteria: 1. Patients with a history of significant cardiac disease (LVEF \<35%, 2nd/3rd-degree block without a pacemaker, or significant arrhythmia) 2. Patients with kidney disease (GFR \<30), or hepatic dysfunction (history of cirrhosis) 3. Allergy or sensitivity to magnesium 4. Patient with neuromuscular disease such as myasthenia graves
About the study
Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.
What is being tested
- Magnesium sulfate administration (drug)
Sponsor: University of California, San Francisco · Participants: 40 · Started: Jul 1, 2025
Contact the study team
- Hemra Cil, MD · Phone: 415-502-7846
Official record on ClinicalTrials.gov — NCT06975072
Locations in the U.S.
| California | University of California San Francisco Hospital, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.